PDS Biotechnology Corp - Common Stock, par value $0.00033 per share (PDSB)

CUSIP: 70465T107

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 7 signals
Share change
+3,988,633
Put/Call ratio
0.8%
SEC-reported price per share
$1.19
Number of holders
46
Value change
+$4,484,828
Number of buys
20
Open additional details 1 more signal available
Number of sells
23
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
102,192,638

Security key

70465T107

Report period

Q1 2025

Institutions

46

Top holders

10

Ownership snapshot

Top reported holders of PDSB - PDS Biotechnology Corp - Common Stock, par value $0.00033 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
DeLyle W. Bloomquist
Disclosed value leader
DeLyle W. Bloomquist
Comparable rows
0/15
Latest evidence
31 Dec 2024
3/4/5 13F Highest disclosed value: $7,813,350 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

DeLyle W. Bloomquist has the largest disclosed position value at $7.81M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens DeLyle W. Bloomquist's linked filing trail.
Disclosed position value Top 5
DeLyle W. Bloomquist $7.81M
VANGUARD GROUP INC $2.45M
BlackRock, Inc. $852.7K
GEODE CAPITAL MANAGEMENT, LLC $680.2K
SUSQUEHANNA INTERNATIONAL GROUP, LLP $402.6K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
DeLyle W. Bloomquist
3/4/5
Resigned as a Director on June 17, 2021.
—
mixed-class rows
$7,813,350
804,941 shares
mixed-class rows
— 16 Jun 2021
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$2,454,474
1,505,812 shares
— 31 Dec 2024
BlackRock, Inc.
13F
Company
13F
—
denominator unverified
$852,722
523,142 shares
— 31 Dec 2024
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$680,222
417,217 shares
— 31 Dec 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
13F
—
denominator unverified
$402,573
246,977 shares
— 31 Dec 2024
CITADEL ADVISORS LLC
13F
Company
13F
—
denominator unverified
$358,950
220,215 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
46
Shares
8,226,452
Rows available
46
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2025 vs Q1 2025 Across Filers

Q1 2025 holders
46
Q1 2025 holders
46
Holder diff
0
Investor Q1 2025 Shares Q1 2025 Shares Share Diff Share Chg % Q1 2025 value Q1 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .